Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
ABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, co...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70997 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330309545328640 |
|---|---|
| author | Jung Sun Kim Youngun Kim Beodeul Kang Ilhwan Kim Hyeyeong Kim Won Suk Lee Jung Yong Hong Ho Yeong Lim Han Sang Kim Chang Gon Kim Sanghoon Jung Chansik An Chan Kim Hong Jae Chon |
| author_facet | Jung Sun Kim Youngun Kim Beodeul Kang Ilhwan Kim Hyeyeong Kim Won Suk Lee Jung Yong Hong Ho Yeong Lim Han Sang Kim Chang Gon Kim Sanghoon Jung Chansik An Chan Kim Hong Jae Chon |
| author_sort | Jung Sun Kim |
| collection | DOAJ |
| description | ABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI exposure, compared with nivolumab (Nivo) monotherapy. Methods We analyzed 204 lesions from Nivo/Ipi‐treated and 305 lesions from Nivo‐treated patients with advanced HCC at five referral cancer centers in Korea. Organ‐specific response criteria were adopted from Response Evaluation Criteria in Solid Tumors 1.1, according to the indicated sites: the liver, lung, lymph nodes (LNs), and other metastatic sites. Results Nivo/Ipi combination therapy showed OSORRs of 18.1% in the liver, 17.7% in the lungs, 30.0% in LNs, and 12.5% in other metastatic sites. Patients without prior ICI exposure had OSORRs of 29.0% in the liver, 31.3% in the lungs, 33.3% in LNs, and 23.1% in other metastatic sites (72 individual lesions). Conversely, patients with prior ICI exposure had OSORRs of 11.5% in the liver, 11.4% in the lung, 27.8% in LNs, and 7.4% in other metastatic sites (132 individual lesions). Furthermore, patients who achieved a response in the liver or the lung had longer progression‐free and overall survival, compared with those without responses. Nivo monotherapy yielded OSORRs of 13.5%, 25.3%, 39.3%, and 18.4% in the liver, lungs, LNs, and other metastatic sites, respectively. Conclusion Nivo/Ipi combination therapy induced superior intrahepatic responses compared to Nivo monotherapy in patients with advanced HCC without prior ICI exposure, highlighting its potential to overcome liver‐specific immune tolerance. |
| format | Article |
| id | doaj-art-85cdc599a9c346f29e27d4ab12a409c4 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-85cdc599a9c346f29e27d4ab12a409c42025-08-20T03:46:58ZengWileyCancer Medicine2045-76342025-06-011411n/an/a10.1002/cam4.70997Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective StudyJung Sun Kim0Youngun Kim1Beodeul Kang2Ilhwan Kim3Hyeyeong Kim4Won Suk Lee5Jung Yong Hong6Ho Yeong Lim7Han Sang Kim8Chang Gon Kim9Sanghoon Jung10Chansik An11Chan Kim12Hong Jae Chon13Medical Oncology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaCHA University School of Medicine Seongnam KoreaMedical Oncology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaDivision of Oncology, Department of Internal Medicine Haeundae Paik Hospital, Inje University College of Medicine Busan KoreaDepartment of Internal Medicine Ulsan University Hospital, University of Ulsan College of Medicine Ulsan KoreaMedical Oncology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaDivision of Hematology‐Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul KoreaDivision of Hematology‐Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul KoreaYonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine Yonsei University College of Medicine Seoul KoreaYonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine Yonsei University College of Medicine Seoul KoreaDepartment of Radiology CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaDepartment of Radiology CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaMedical Oncology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaMedical Oncology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine Seongnam KoreaABSTRACT Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab plus ipilimumab (Nivo/Ipi) combination treatment, considering prior ICI exposure, compared with nivolumab (Nivo) monotherapy. Methods We analyzed 204 lesions from Nivo/Ipi‐treated and 305 lesions from Nivo‐treated patients with advanced HCC at five referral cancer centers in Korea. Organ‐specific response criteria were adopted from Response Evaluation Criteria in Solid Tumors 1.1, according to the indicated sites: the liver, lung, lymph nodes (LNs), and other metastatic sites. Results Nivo/Ipi combination therapy showed OSORRs of 18.1% in the liver, 17.7% in the lungs, 30.0% in LNs, and 12.5% in other metastatic sites. Patients without prior ICI exposure had OSORRs of 29.0% in the liver, 31.3% in the lungs, 33.3% in LNs, and 23.1% in other metastatic sites (72 individual lesions). Conversely, patients with prior ICI exposure had OSORRs of 11.5% in the liver, 11.4% in the lung, 27.8% in LNs, and 7.4% in other metastatic sites (132 individual lesions). Furthermore, patients who achieved a response in the liver or the lung had longer progression‐free and overall survival, compared with those without responses. Nivo monotherapy yielded OSORRs of 13.5%, 25.3%, 39.3%, and 18.4% in the liver, lungs, LNs, and other metastatic sites, respectively. Conclusion Nivo/Ipi combination therapy induced superior intrahepatic responses compared to Nivo monotherapy in patients with advanced HCC without prior ICI exposure, highlighting its potential to overcome liver‐specific immune tolerance.https://doi.org/10.1002/cam4.70997advanced HCCimmune checkpoint inhibitorNivolumab monotherapyNivolumab plus ipilimumaborgan‐specific objective response rateprior ICI treatment |
| spellingShingle | Jung Sun Kim Youngun Kim Beodeul Kang Ilhwan Kim Hyeyeong Kim Won Suk Lee Jung Yong Hong Ho Yeong Lim Han Sang Kim Chang Gon Kim Sanghoon Jung Chansik An Chan Kim Hong Jae Chon Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study Cancer Medicine advanced HCC immune checkpoint inhibitor Nivolumab monotherapy Nivolumab plus ipilimumab organ‐specific objective response rate prior ICI treatment |
| title | Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study |
| title_full | Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study |
| title_fullStr | Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study |
| title_full_unstemmed | Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study |
| title_short | Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study |
| title_sort | organ specific responses to nivolumab plus ipilimumab in advanced hepatocellular carcinoma a multicenter retrospective study |
| topic | advanced HCC immune checkpoint inhibitor Nivolumab monotherapy Nivolumab plus ipilimumab organ‐specific objective response rate prior ICI treatment |
| url | https://doi.org/10.1002/cam4.70997 |
| work_keys_str_mv | AT jungsunkim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT youngunkim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT beodeulkang organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT ilhwankim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT hyeyeongkim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT wonsuklee organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT jungyonghong organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT hoyeonglim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT hansangkim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT changgonkim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT sanghoonjung organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT chansikan organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT chankim organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy AT hongjaechon organspecificresponsestonivolumabplusipilimumabinadvancedhepatocellularcarcinomaamulticenterretrospectivestudy |